Continuous ultrafiltration for congestive heart failure: the CUORE trial

Area of Science:

• Cardiology
• Nephrology
• Critical Care Medicine

Context:

• Severe congestive heart failure (HF) with overt fluid overload presents significant management challenges.
• Limited comparative data exist for first-line treatments, specifically ultrafiltration versus standard medical therapy.
• This study addresses the need for evidence in managing fluid overload in hospitalized HF patients.

Purpose:

• To compare the efficacy of ultrafiltration versus standard medical therapy as a first-line treatment for severe congestive heart failure.
• To evaluate the impact on rehospitalization rates for HF over a 1-year follow-up period.
• To assess secondary outcomes including renal function, diuretic requirements, and mortality.

Summary:

• Fifty-six patients with severe HF and fluid overload were randomized to ultrafiltration or standard therapy.
• Despite similar initial weight loss, the ultrafiltration group showed significantly fewer HF rehospitalizations (P = .002) over 1 year.
• Benefits included stable renal function, consistent furosemide dosage, and lower B-type natriuretic peptide levels.

Impact:

• First-line ultrafiltration demonstrates a significant reduction in rehospitalizations for congestive heart failure.
• Ultrafiltration promotes prolonged clinical stabilization in patients with severe fluid overload.
• This treatment strategy offers a promising alternative for managing refractory fluid overload in heart failure.